Australian Biotech Firm Ferronova Initiates Clinical Trial for FerroTrace® Nanoparticle Technology in Gastric and Oesophageal Cancers

Australian biotech company Ferronova has announced the initiation of a clinical trial of the company’s FerroTrace® nanoparticle technology in pat...

April 10, 2024 | Wednesday | News
Denovo Biopharma's Liafensine Shows Promise in Phase 2b Trial for Treatment-Resistant Depression

Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its bi...

April 09, 2024 | Tuesday | News
Shorla Oncology's Palatable Oral Liquid for Leukemia Enters FDA Review Process

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced  that the U.S. Food and Drug Administration (FDA) h...

April 08, 2024 | Monday | News
Standard BioTools Partners with Bristol Myers Squibb to Utilize SomaScan® Platform in Multi-Year Clinical Trials Engagement

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ –...

April 04, 2024 | Thursday | News
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

  Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company specializing in allosteric modulation-based drug development,...

April 03, 2024 | Wednesday | News
Voydeya Approved as Add-On Therapy for Rare PNH Treatment in the US

Voydeya (danicopan) has been granted approval in the United States as an add-on therapy for the treatment of extravascular haemolysis (EVH) in adults diagn...

April 02, 2024 | Tuesday | News
LISCure Biosciences' LB-P8 Granted Fast Track Designation by FDA for Primary Sclerosing Cholangitis Treatment

LISCure Biosciences, a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative microbiome-based therapies, a...

April 01, 2024 | Monday | News
Akebia's Vafseo® Receives FDA Approval as New Oral Standard of Care for Anemia in Dialysis Patients

   Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

March 28, 2024 | Thursday | News
HUTCHMED's Savolitinib Advances for Expanded Approval in China, Promising New Hope for Lung Cancer Patients

  — If approved, would confirm 2021 conditional approval and expand indication to more patients — HUTCHMED (China) Lim...

March 28, 2024 | Thursday | News
Croda International Plc and AAHI Partner to Advance Global Access to Next-Generation Vaccine Adjuvants

Croda International Plc (Croda) and The Access to Advanced Health Institute (AAHI) are pleased to announce the signing of a partnership agreement around in...

March 21, 2024 | Thursday | News
Merck Announces Positive Data on V116, a Promising Pneumococcal Vaccine for Adults

    The trials demonstrated V116's effectiveness in generating immune responses across all 21 serotypes covered by the vaccine in diverse adult...

March 20, 2024 | Wednesday | News
Clarity Pharmaceuticals Advances Theranostic Prostate Cancer Trial to Multi-Dose Phase

    The completion of Cohort 3 marks a significant milestone, with six participants receiving therapy with 67Cu-SAR-bisPSMA at the highest sing...

March 18, 2024 | Monday | News
Optinose's XHANCE Receives FDA Approval for Chronic Sinusitis Treatment, Marking a Milestone in Patient Care

Optinose, a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy conditions, has achieved a significant milestone ...

March 18, 2024 | Monday | News
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company specializing in endocrine diseases and tumors, revealed encouraging...

March 13, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in